Highlights the critical unmet clinical need for effective therapies to prevent myocardial reperfusion injury in patients treated for acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
Underscores unmet need for cardioprotection in acute MI; leaves open discovery of effective therapeutic targets.
Acute myocardial infarction (MI) is a major cause of death and disability worldwide. In patients with MI, the treatment of choice for reducing acute myocardial ischemic injury and limiting MI size is timely and effective myocardial reperfusion using either thombolytic therapy or primary percutaneous coronary intervention (PPCI). However, the process of reperfusion can itself induce cardiomyocyte death, known as myocardial reperfusion injury, for which there is still no effective therapy. A number of new therapeutic strategies currently under investigation for preventing myocardial reperfusion injury have the potential to improve clinical outcomes in patients with acute MI treated with PPCI.
No takes yet. Share an insight, caveat, or question.
Hausenloy et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: